An enzyme inhibitor that helps repair DNA damage may provide a new way to boost the effectiveness of radiation therapy for a lethal type of brain cancer.
In yet another sign that the R&D side of Merck KGaA has derailed and can't get back on track, the pharma giant today said that a late-stage study of a brain cancer drug hopeful had failed to demonstrate signs of efficacy.
A new small-molecule drug developed by cancer researchers has a remarkable effect in mice--it jump-starts a tumor-destroying system in the body, essentially driving cancer cells to suicide while protecting healthy tissue.
Adding in a small molecule enzyme inhibitor to cancer chemotherapy could improve treatment of glioblastoma, a deadly brain cancer, according to U.S. preclinical research published in Molecular Cancer Therapeutics .
A team of researchers at Duke University Medical Center has created a synthetic protein, known as a BiTE (bispecific T-cell engager) that hooks together brain tumor cells and immune cells, like Velcro. This redirects the immune response to kill the cancer cells without affecting healthy cells.
When confronted with an anti-cancer virus, the immune system of a patient with rapidly advancing brain tumors kicks into action, generating natural killer cells to destroy what it sees as an invasion, scientists at Ohio State University and colleagues have found.
Roche, the biggest cancer drug provider in the world, has made progress in building on its blockbuster franchise for the anti-tumor drug Avastin with results of a Phase III study that shows the drug used in combination with radiation and chemotherapy improved progression-free survival in patients newly diagnosed with glioblastoma.
Researchers at Northwestern Brain Tumor Institute are working to figure out whether a vaccine made from a patient's own white blood cells can be used to attack cancers by slowing the growth of tumors.
Another site in the U.S. has begun recruiting for a Phase II clinical trial of Northwest Biotherapeutics' DCVax-L personalized brain cancer vaccine for the treatment of glioblastoma multiforme.
Phase II data for Agenus' HSPPC-96 vaccine (also known as vitespen) showed glioblasoma patients living longer, which could offer a glimmer of hope.